top of page

X4 Pharma's CEO on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications

  • blonca9
  • Jun 7, 2024
  • 1 min read

Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4 will have in chronic neutropenia towards the end of the month.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

bottom of page